초록 열기/닫기 버튼
Purpose This study was conducted to evaluate outcomes in adult patients with Burkitt lymphoma(BL) or Burkitt-like lymphoma treated with an rituximab plus hyper-CVAD (R-hyper-CVAD)regimen by focusing on tolerability and actual delivered relative dose intensity (RDI). Materials and MethodsPatients 20 years of age and pathologically diagnosed with BL or Burkitt-like lymphomawere treated with at least one cycle of R-hyper-CVAD as the first-line treatment in thisstudy. Eligible patients’ case report forms were requested from their physicians to obtainclinical and laboratory data for this retrospective study. ResultsForty-three patients (median age, 51 years) from 14 medical centers in Korea wereanalyzed, none of which were infected with human immunodeficiency virus. The majority ofpatients had advanced diseases, and 24 patients achieved a complete response (75.0%). After a median follow-up period of 20.0 months, 2-year event-free and overall survival rateswere 70.9% and 81.4%, respectively. Eleven patients (25.6%) were unable to complete theR-hyper-CVAD regimen, including six patients due to early death. The RDIs of adriamycin,vincristine, methotrexate, and cytarabine were between 60% and 65%, which means lessthan 25% of patients received greater than 80% of the planned dose of each drug. Poorperformance status was related to the lower RDIs of doxorubicin and methotrexate. ConclusionR-hyper-CVAD showed excellent treatment outcomes in patients who were suitable fordose-intense chemotherapy. However, management of patients who are intolerant to adose-intense regimen remains problematic due to the frequent occurrence of treatmentrelatedcomplications.
